Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Feb 26

PMID 38405578

Authors

Xiang-Yu Ji

Cheng-Jing Lei

Shuang Kong

Han-Fei Li

Si-Yu Pan

Yu-Jing Chen

Fan-Rong Zhao

Tian-Tian Zhu

Affiliations

Soon will be listed here.

Abstract

Purpose: The underlying causes of pulmonary arterial hypertension (PAH) often remain obscure. Addressing PAH with effective treatments presents a formidable challenge. Studies have shown that Hydroxysafflor yellow A (HSYA) has a potential role in PAH, While the mechanism underlies its protective role is still unclear. The study was conducted to investigate the potential mechanisms of the protective effects of HSYA.

Methods: Using databases such as PharmMapper and GeneCards, we identified active components of HSYA and associated PAH targets, pinpointed intersecting genes, and constructed a protein-protein interaction (PPI) network. Core targets were singled out using Cytoscape for the development of a model illustrating drug-component-target-disease interactions. Intersection targets underwent analysis for Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Selected components were then modeled for target interaction using Autodock and Pymol. In vivo validation in a monocrotaline-induced PAH (MCT-PAH) animal model was utilized to substantiate the predictions made by network pharmacology.

Results: We associated HSYA with 113 targets, and PAH with 1737 targets, identifying 34 mutual targets for treatment by HSYA. HSYA predominantly affects 9 core targets. Molecular docking unveiled hydrogen bond interactions between HSYA and several PAH-related proteins such as ANXA5, EGFR, SRC, PPARG, PGR, and ESR1.

Conclusion: Utilizing network pharmacology and molecular docking approaches, we investigated potential targets and relevant human disease pathways implicating HSYA in PAH therapy, such as the chemical carcinogenesis receptor activation pathway and the cancer pathway. Our findings were corroborated by the efficacious use of HSYA in an MCT-induced rat PAH model, confirming its therapeutic potential.

Citing Articles

Alisol A, the Eye-Entering Ingredient of , Relieves Macular Edema Through TNF-α as Revealed by UPLC-Triple-TOF/MS, Network Pharmacology, and Zebrafish Verification.

Shen R, Cheng K, Li G, Pan Z, Qiaolongbatu X, Wang Y Drug Des Devel Ther. 2024; 18:3361-3382.

PMID: 39100223 PMC: 11297588. DOI: 10.2147/DDDT.S468119.

References

Hajra A, Safiriyu I, Balasubramanian P, Gupta R, Chowdhury S, Prasad A . Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Curr Probl Cardiol. 2022; 48(8):101236. PMC: 9171713. DOI: 10.1016/j.cpcardiol.2022.101236. View

Sun X, Wei X, Qu S, Zhao Y, Zhang X . Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats. Bioorg Med Chem Lett. 2010; 20(14):4120-4. DOI: 10.1016/j.bmcl.2010.05.076. View

Hu W, Xie L, Hao S, Wu Q, Xiang G, Li S . Protective effects of progesterone on pulmonary artery smooth muscle cells stimulated with Interleukin 6 via blocking the shuttling and transcriptional function of STAT3. Int Immunopharmacol. 2021; 102:108379. DOI: 10.1016/j.intimp.2021.108379. View

Liu J, Cai G, Li M, Fan S, Yao B, Ping W . Fibroblast growth factor 21 attenuates hypoxia-induced pulmonary hypertension by upregulating PPARγ expression and suppressing inflammatory cytokine levels. Biochem Biophys Res Commun. 2018; 504(2):478-484. DOI: 10.1016/j.bbrc.2018.09.004. View

Jacobs W, van de Veerdonk M, Trip P, de Man F, Heymans M, Marcus J . The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest. 2013; 145(6):1230-1236. PMC: 4042511. DOI: 10.1378/chest.13-1291. View

Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. DOI: 10.1056/NEJMoa012212. View

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View

Galie N, Ghofrani H, Torbicki A, Barst R, Rubin L, Badesch D . Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353(20):2148-57. DOI: 10.1056/NEJMoa050010. View

Umar S, Partow-Navid R, Ruffenach G, Iorga A, Moazeni S, Eghbali M . Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy. Biol Sex Differ. 2017; 8:9. PMC: 5360087. DOI: 10.1186/s13293-017-0129-7. View

10.

Norton C, Sheak J, Yan S, Weise-Cross L, Jernigan N, Walker B . Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling. Am J Respir Cell Mol Biol. 2019; 62(1):61-73. PMC: 6938133. DOI: 10.1165/rcmb.2018-0106OC. View

11.

Yoshida S, Minematsu N, Chubachi S, Nakamura H, Miyazaki M, Tsuduki K . Annexin V decreases PS-mediated macrophage efferocytosis and deteriorates elastase-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol. 2012; 303(10):L852-60. DOI: 10.1152/ajplung.00066.2012. View

12.

Tuder R . Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2016; 367(3):643-649. PMC: 5408737. DOI: 10.1007/s00441-016-2539-y. View

13.

Norton C, Broughton B, Jernigan N, Walker B, Resta T . Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2. Antioxid Redox Signal. 2012; 18(14):1777-88. PMC: 3619151. DOI: 10.1089/ars.2012.4836. View

14.

Cai G, Liu J, Wang M, Su L, Cai M, Huang K . Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension. Exp Biol Med (Maywood). 2019; 244(3):252-261. PMC: 6425103. DOI: 10.1177/1535370219828692. View

15.

Matori H, Umar S, Nadadur R, Sharma S, Partow-Navid R, Afkhami M . Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012; 60(2):425-30. PMC: 4252152. DOI: 10.1161/HYPERTENSIONAHA.112.191445. View

16.

Han X, Zhang Y, Zhou Z, Zhang X, Long Y . Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats. J Int Med Res. 2016; 44(3):569-84. PMC: 5536702. DOI: 10.1177/0300060515597931. View

17.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

18.

Eberhardt J, Santos-Martins D, Tillack A, Forli S . AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021; 61(8):3891-3898. PMC: 10683950. DOI: 10.1021/acs.jcim.1c00203. View

19.

Bai Y, Lu P, Han C, Yu C, Chen M, He F . Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery. Molecules. 2013; 17(12):14918-27. PMC: 6268686. DOI: 10.3390/molecules171214918. View

20.

De Kock L, Freson K . The (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes. Medicina (Kaunas). 2020; 56(12). PMC: 7759910. DOI: 10.3390/medicina56120633. View